Jazz Pharmaceuticals PLC
JAZZ: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$552.00 | Hqjq | Swkxfqf |
Jazz Reports Mixed Q1 but Xyrem Growth Stays Strong; Lowering FVE to $130 From Virus Impact to Sales
Jazz reported mixed first-quarter results, with key drug Xyrem for sleep disorders driving top-line growth, but recently launched Sunosi posting disappointing sales numbers. Further, the company's bottom line suffered from a $136 million impairment charge due to the termination of a phase 3 trial of Defitelio in the prevention of veno-occlusive disease after an interim analysis indicated it would likely not reach statistical significance.